My Experience with Human
Growth Hormone
My fibromyalgia was severely aggravated by an accident in
January of 1997. It got so bad, that I had flares, including fever, aches
and severe pain, several times per week. I missed many days at work and
was severely depressed. I became so weak that I couldn't walk up a flight
of stairs without feeling like I was going to collapse. I caught every cold and
flu that came along. Then, I was told about human growth hormone (HGH)
and, like some many other things that were "supposed" to help me, I
was hesitant to try it because I couldn't bear another disappointment. I
had hoped that, at least, it would prevent me from getting so many colds and
infections. I began taking it May 29, 1999 and, in less than a week, my
energy level had significantly increased. By the second week, I could run
up a flight of stairs without huffing and puffing. I did not have a single
flare in almost 8 weeks until July 23, 1999, after suffering from major
emotional trauma. However, by the next day, the flare had resolved.
I have never been so impressed with a product before in my life. I am so
impressed, that I'm now selling the product so that other people can, hopefully,
get relief. We are now in the height of allergy season and I haven't taken
medication. I cannot guarantee that it will work this well on you or on
your friend or family member with fibromyalgia. All I want to do is to
share my experience and hope that other people will benefit from this wonderful
product.
Clinical Supporting Evidence
for My Results
| TITLE:
| Disordered growth hormone secretion
in fibromyalgia: a review of recent findings and a hypothesized etiology.
| AUTHORS:
| Bennett RM
| AUTHOR AFFILIATION:
| Dept. Medicine (L329A), Oregon
Health Sciences University, Portland 97201, USA.
| SOURCE:
| Z Rheumatol 1998;57 Suppl 2:72-6
| CITATION IDS:
| PMID: 10025088 UI: 99149227
| ABSTRACT:
| Growth hormone (GH) deficiency
occurs in about 30% of fibromyalgia patients. Treatment of GH deficient
fibromyalgia patients with recombinant growth hormone improves several
clinical features, including the tender point count. Defective GH
secretion in these patients appears to be due to increased somatostatin
tone in the hypothalamus. An hypothesis is presented which relates
dysfunctional GH secretion to the effects of intermittent
hypercortisolemia on upregulating the density of beta-adrenergic receptors
in the hypothalamus. The resulting augmentation of beta-adrenergic tone
stimulates the release of somatostatin, thus, impairing GH secretion.
|
| | | | |
| TITLE:
| A randomized, double-blind,
placebo-controlled study of growth hormone in the treatment of
fibromyalgia.
| AUTHORS:
| Bennett RM; Clark SC; Walczyk J
| AUTHOR AFFILIATION:
| Department of Medicine, Oregon
Health Sciences University, Portland 97201, USA.
| SOURCE:
| Am J Med 1998 Mar;104(3):227-31
| CITATION IDS:
| PMID: 9552084 UI: 98211811
| ABSTRACT:
| PURPOSE: The cause of fibromyalgia
(FM) is not known. Low levels of insulin-like growth factor 1 (IGF-1), a
surrogate marker for low growth hormone (GH) secretion, occur in about one
third of patients who have many clinical features of growth hormone
deficiency, such as diminished energy, dysphoria, impaired cognition, poor
general health, reduced exercise capacity, muscle weakness, and cold
intolerance. To determine whether suboptimal growth hormone production
could be relevant to the symptomatology of fibromyalgia, we assessed the
clinical effects of treatment with growth hormone. METHODS: Fifty women
with fibromyalgia and low IGF-1 levels were enrolled in a randomized,
placebo-controlled, double-blind study of 9 months' duration. They gave
themselves daily subcutaneous injections of growth hormone or placebo. Two
outcome measures--the Fibromyalgia Impact Questionnaire and the number of
fibromyalgia tender points-were evaluated at 3-monthly intervals by a
blinded investigator. An unblinded investigator reviewed the IGF-1 results
monthly and adjusted the growth hormone dose to achieve an IGF- 1 level of
about 250 ng/mL. RESULTS: Daily growth hormone injections resulted in a
prompt and sustained increase in IGF-1 levels. The treatment (n=22) group
showed a significant improvement over the placebo group (n=23) at 9 months
in both the Fibromyalgia Impact Questionnaire score (P <0.04) and the
tender point score (P <0.03). Fifteen subjects in the growth hormone
group and 6 subjects in the control group experienced a global improvement
(P <0.02). There was a delayed response to therapy, with most patients
experiencing improvement at the 6-month mark. After discontinuing growth
hormone, patients experienced a worsening of symptoms. Carpal tunnel
symptoms were more prevalent in the growth hormone group (7 versus 1); no
other adverse events were more common in this group. CONCLUSIONS: Women
with fibromyalgia and low IGF-1 levels experienced an improvement in their
overall symptomatology and number of tender points after 9 months of daily
growth hormone therapy. This suggests that a secondary growth hormone
deficiency may be responsible for some of the symptoms of fibromyalgia.
|
| | | | |
|
